Biopool 10-K (03/30/98) - Market & Competition Excerpt
MARKETS AND COMPETITION
The Company believes that the worldwide market for in vitro diagnostics is approximately $18-20 billion and that the existing market for blood coagulation, fibrinolysis, and thrombotic risk factors is approximately $600 million. The total worldwide blood group serology market is approximately $300 million. The Company's current product range thus addresses a worldwide market of approximately $1 billion.
In the blood group serology business, major competitors include Ortho, Immucor, and Gamma Biologicals, with approximately 45%, 27%, and 15% U.S. market share, respectively. The BCA products enjoy an approximate 5% U.S. market share. In addition to these same competitors worldwide, other competitors include Diamed (Switzerland), Biotest (Germany), and Diagast (France). BCA products have a non-U.S. market share of approximately 1%.
sec.gov
Food for thought!
Tom |
